Characterizing the Genotype and Phenotype in Adults With Bardet-Biedl Syndrome

Bardet-Biedl Syndrome Clinical Trial

Official title:

Characterizing the Genotype, Phenotype, Health Issues, and Quality of Life in Adults With Bardet-Biedl Syndrome

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

• NCT number: NCT05400278
• Other study ID #: 166639
• Status: Enrolling by invitation
• Start date: February 1, 2022
• Est. completion date: December 31, 2026

Study information

• Verified date: May 2022
• Source: Oslo University Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Bardet-Biedl syndrome (BBS; OMIN #209900) is a rare genetic disorder characterized by six core features: rod-cone dystrophy (retinitis pigmentosa), polydactyly, obesity, genital anomalies, renal anomalies, and learning difficulties. This study aims to contribute to genetic and medical knowledge of BBS, and to provide information on quality of life in adults with BBS and their close relatives. Participants will undergo medical assessments (ocular, oral, and physical examinations) and self-reporting of quality of life, diet, cognitive and emotional symptoms. There are some known genotype-phenotype associations in BBS and participants will be offered genetic testing. It is important to map both genotype and associated phenotype in order to provide optimal treatment and follow-up. Individuals with BBS, age 16 years or older, will be invited to participate. The investigators expect to enroll at least 25 male and female adults with BBS and 15 of their parents to participate in qualitative interviews. These interviews will investigate parents' experiences having a child with BBS, satisfaction with health care services, experience with social and family life, and psychological health.

Description:

Improved care for adults with BBS living in Norway necessitates increased knowledge of pertinent health-related, emotional, and educational, employment and psychosocial issues. Adults with BBS living in Norway may face new challenges and have unmet healthcare needs. Therefore, the investigators intend to evaluate the adult with BBS as a person with special needs (e.g. need for support systems, lack of social opportunities, and mental health problems) and long-term challenges.This project will describe the visual, medical, physical, nutritional, and psychological difficulties experienced by people with BBS. The planned multi-disciplinary clinical evaluation in this study can help address the existing knowledge gaps. Relatives who help their loved ones with various activities of daily living may experience reduced quality of life and altered social roles. Therefore, the investigators also want to study the quality of life and psychological status of close relatives. This project might contribute information for new clinical protocols and suggest areas for further research in genetics, healthcare needs and quality of life for people living with BBS.

Recruitment information / eligibility

• Status: Enrolling by invitation
• Enrollment: 40
• Est. completion date: December 31, 2026
• Est. primary completion date: December 31, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 16 Years to 80 Years

Eligibility

Inclusion Criteria:

Individuals diagnosed with BBS (see below), age 16 years or older. BBS is characterized by six core features : rod-cone dystrophy (retinitis pigmentosa), polydactyly, obesity, genital anomalies, renal anomalies, and learning difficulties.

Additional features include speech delay, developmental delay, diabetes mellitus, dental anomalies, congenital heart disease, brachydactyly (shortening of fingers/toes), ataxia, and anosmia/hyposmia (deficienct sense of smell). A minimum of four of the core features, or three core features and two additional features are required for the clinical diagnosis of BBS.

Exclusion Criteria:

Individuals age < 16 years, current severe illness or known diagnosis of autism.

Related Conditions & MeSH terms

• Bardet-Biedl Syndrome
• Syndrome

Intervention

Other:
• No intervention
No intervention

Locations

Country	Name	City	State
Norway	Oslo University Hospital	Oslo

Sponsors (3)

Lead Sponsor	Collaborator
Oslo University Hospital	Lovisenberg Diakonale Hospital, Sykehuset Telemark

Country where clinical trial is conducted

Norway, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The Medical Outcome Study 36-item Short Form Health Survey (SF-36)	Health related quality of life (HRQOL) including measures of Physical and mental HRQOL. The SF-36 is a generic quality of life scale which has been validated in Norway. SF-36 evaluates eight domains of health: physical functioning, role limitation due to physical problems, bodily pain, general perception of health, social functioning, role limitations due to emotional functioning, vitality and mental health. Items on each scale are summed to yield a score from 0-100. A higher score means better quality of life. A license from Quality Metric is used for scoring (License number QM051240). The eight domains are summarized into physical component summary scores and mental component summary scores.	Feb 2022-Dec 2026
Primary	Needs and Provision Complexity Scale	Presence of health care needs. This is an interview that evaluates the needs for healthcare and social support services. It has two parts: Part A (Needs) is completed by the clinician to evaluate each patient's need for health and social care; and Part B (Gets) is to evaluate to which these needs are met through the services that have been provided, based on information provided by the patient and a close relative. Each part includes 15 items with a total scoring range of 0-50 covering low and high levels of needs. There are six subscales representing two domains: Health and personal care needs, and Social and support needs. This scale was developed in the UK for neurological conditions and has been translated and used in Norway.	Feb 2022-Dec 2026
Primary	Behavioral Rating Inventory of Executive Function- Adult Version	Assessing cognitive problems. BRIEF-A is a measure of everyday executive functions using self-reports. It includes 75 items that assess nine aspects of executive functioning symptoms of everyday life. Raw scores are transformed into age-corrected T-scores. Higher T-scores mean better executive function.	Feb 2022-Dec 2026
Secondary	Short Physical Performance Battery;	Assessing physical problems. This is a group of measures that combines the results of the gait speed, chair stand and balance tests. The scores range from 0 (worst performance) to 12 (best performance).It has been used as a predictive tool for possible disability.	Feb 2022-Dec 2026
Secondary	The Hospital Anxiety and Depression Scale;	Assessing anxiety and depression symptoms. This is a generic instrument used to address symptoms of depression and anxiety. The two subscales (anxiety, depression) consist of seven items rated on a four-point scale from 0 (no symptom) to three (severe symptom). A score of >7 on either subscale indicates at least a mild level of depressive or anxiety symptoms. A total HADS score may be used as a global measure of psychological distress. It is widely used in various somatic and psychiatric populations.	Feb 2022-Dec 2026
Secondary	Three Factor Eating Questionnaire-R21	Assessing eating habits. This is a frequently used validated scale that measures three domains of eating behavior (cognitive restraint, uncontrolled eating and emotional eating). The first 20 items are rated on a 4-point Likert scale and the item 21 is answered through an 8-point Likert scale. Scores range from 0-100, with higher scores being indicative of greater restraint eating.	Feb 2022-Dec 2026